Regulatory
MyoKardia, Inc. announced updates related to its hypertrophic cardiomyopathy treatment portfolio, including lead therapeutic candidate, mavacamten.
Adocia, the clinical-stage biopharmaceutical company focused on the treatment of diabetes and other metabolic diseases with innovative formulations of proteins and peptides, announces its financial results for the first six months ended June 30, 2019.
Atriva Therapeutics GmbH announced that they have received the Biomarker Validation Award as part of the European Interreg Project Codex4SME.
Eisai has received a New Drug Approval for its in-house developed anticancer agent Halaven for use in the treatment of patients with locally advanced or metastatic breast cancer, previously treated with at least two prior chemotherapy regimens, including an anthracycline and a taxane, from the China National Medical Products Administration.
A federal judge ordered that information on sales of opioids up to the year 2013 could be released.
As the 2020 election heats up, candidates for president are unveiling their plans to lower prescription drug prices.
Phase 1/2 trial to be HOOKIPA’s first clinical trial in immuno-oncology
Although the American public, Congress and the Trump administration have pressed for meaningful legislation over drug pricing, time is running out this year.
The Sackler family has earned billions from the sale of OxyContin and the backlash against the family has increased in-fighting, according to reports.
Turning away from “low-value” (waste, overuse) towards “high-value” health care is critical for the sustainability of solidarity-based healthcare systems. The Ludwig Boltzmann Institute for Health Technology Assessment is represented on the European Expert Panel.
PRESS RELEASES